Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bioheart Inc. (USRM : OTC)

• Company Description    U.S. Stem cell, Inc. is engaged in the regenerative medicine / cellular therapy industry. The company focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. Its operating division consists of US Stem Cell Training, Vetbiologics and US Stem Cell Clinic. US Stem Cell, Inc., formerly known as Bioheart, Inc., is headquartered in Sunrise, Florida. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.01 Daily Weekly Monthly 20 Day Moving Average: 496,667 shares Shares Outstanding: 595.60 (millions) Market Capitalization: $3.99 (millions) Beta: -0.58 52 Week High: $0.03 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.94% 1.89% 12 Week -21.18% -11.41% Year To Date 11.67% 36.42%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR - SUNRISE,FL 33323 USA ph: 954-835-1500 fax: 954-845-9976 rmadaris@bioheartinc.com http://www.us-stemcell.com

• General Corporate Information    Officers Mike Tomas - Chief Executive Officer; Chief Financial Officer Mark P. Borman - Chairman of the Board William P. Murphy Jr - Director; Chairman Emeritus Sheldon Anderson - Director Greg Knutson - Director Peer Information Bioheart Inc. (CORR.) Bioheart Inc. (RSPI) Bioheart Inc. (CGXP) Bioheart Inc. (BGEN) Bioheart Inc. (GTBP) Bioheart Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90350U100 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/21 Next Expected EPS Date: 07/15/22 Share - Related Items Shares Outstanding: 595.60 Most Recent Split Date: 11.00 (0.00:1) Beta: -0.58 Market Capitalization: $3.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 19.97 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -79.27% vs. Previous Quarter: -58.17% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - -1,353.11 09/30/21 - -1,283.06 Current Ratio 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.01 Quick Ratio 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.01 Operating Margin 03/31/22 - - 12/31/21 - -1,644.78 09/30/21 - -1,112.03 Net Margin 03/31/22 - - 12/31/21 - -1,644.78 09/30/21 - -1,112.03 Pre-Tax Margin 03/31/22 - - 12/31/21 - -1,635.32 09/30/21 - -1,111.68 Book Value 03/31/22 - - 12/31/21 - -0.03 09/30/21 - -0.03 Inventory Turnover 03/31/22 - - 12/31/21 - 19.70 09/30/21 - 13.85 Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©